- Non-invasive, drug-free treatment with no sedation or downtime
- Targets brain regions involved in mood regulation to support lasting symptom relief
- Can improve depression, anxiety, focus, motivation, and emotional balance
- Well-tolerated and safe, with sessions completed while fully awake
- Backed by strong clinical evidence for treatment-resistant depression
- Individuals with depression who haven’t found enough relief from medication or therapy alone
- People seeking non-medication or low-side-effect treatment options
- Those experiencing persistent low mood, lack of motivation, or cognitive fog
- Individuals with anxiety, OCD, or related mood disorders (case-dependent)
- Clients looking to complement psychotherapy with a neurobiological approach
rTMS is FDA-approved for treatment-resistant depression.
This means it has strong clinical evidence demonstrating safety and effectiveness.
rTMS can increase neuroplasticity, the brain’s ability to form new connections.
This helps explain why mood improvements continue even after treatment ends (Fitzsimmons et al., 2024).
rTMS targets the left dorsolateral prefrontal cortex, a region often underactive in depression.
Stimulating this area can restore healthier activity patterns linked to mood regulation (Fox et al., 2012).
Sessions require no anesthesia and have no systemic side effects.
Unlike medications, rTMS acts locally on the brain without affecting the rest of the body.
rTMS is also being studied for anxiety, PTSD, OCD, and chronic pain.
This reflects growing evidence of its impact on neural circuits beyond mood.